BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30873664)

  • 21. EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer.
    Wu Q; Chen Z; Zhang G; Zhou W; Peng Y; Liu R; Chen C; Feng J
    Acta Biochim Biophys Sin (Shanghai); 2018 Jul; 50(7):693-700. PubMed ID: 29790898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2.
    Chen H; Pan H; Qian Y; Zhou W; Liu X
    Mol Cancer; 2018 Jan; 17(1):4. PubMed ID: 29310680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
    Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
    Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD.
    Song H; Li D; Wu T; Xie D; Hua K; Hu J; Deng X; Ji C; Deng Y; Fang L
    BMB Rep; 2018 Nov; 51(11):602-607. PubMed ID: 30269739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p.
    Li S; Zhou J; Wang Z; Wang P; Gao X; Wang Y
    Biomed Pharmacother; 2018 Aug; 104():451-457. PubMed ID: 29793177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-103 regulates triple negative breast cancer cells migration and invasion through targeting olfactomedin 4.
    Xiong B; Lei X; Zhang L; Fu J
    Biomed Pharmacother; 2017 May; 89():1401-1408. PubMed ID: 28320108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.
    He R; Liu P; Xie X; Zhou Y; Liao Q; Xiong W; Li X; Li G; Zeng Z; Tang H
    J Exp Clin Cancer Res; 2017 Oct; 36(1):145. PubMed ID: 29037220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.
    Tang H; Liu P; Yang L; Xie X; Ye F; Wu M; Liu X; Chen B; Zhang L; Xie X
    Mol Cancer Ther; 2014 Dec; 13(12):3185-97. PubMed ID: 25319390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
    Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
    Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3.
    Bai X; Han G; Liu Y; Jiang H; He Q
    Biomed Pharmacother; 2018 Jul; 103():1482-1489. PubMed ID: 29864933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-922 regulates apoptosis, migration, and invasion by targeting SOCS1 in gastric cancer.
    Shayimu P; Wang JB; Liu L; Tuerdi R; Yu CG; Yusufu A
    Kaohsiung J Med Sci; 2020 Mar; 36(3):178-185. PubMed ID: 31709719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Knockdown of long non-coding RNA TP73-AS1 suppresses triple negative breast cancer cell vasculogenic mimicry by targeting miR-490-3p/TWIST1 axis.
    Tao W; Sun W; Zhu H; Zhang J
    Biochem Biophys Res Commun; 2018 Oct; 504(4):629-634. PubMed ID: 30193732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CCAT1 promotes triple-negative breast cancer progression by suppressing miR-218/ZFX signaling.
    Han C; Li X; Fan Q; Liu G; Yin J
    Aging (Albany NY); 2019 Jul; 11(14):4858-4875. PubMed ID: 31310241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
    Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
    Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation.
    Dong G; Liang X; Wang D; Gao H; Wang L; Wang L; Liu J; Du Z
    Med Oncol; 2014 Jul; 31(7):57. PubMed ID: 24930006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene.
    Tsouko E; Wang J; Frigo DE; Aydoğdu E; Williams C
    Carcinogenesis; 2015 Sep; 36(9):1051-60. PubMed ID: 26088362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA‑27a promotes tumorigenesis via targeting AKT in triple negative breast cancer.
    Wu J; Sun Z; Sun H; Li Y
    Mol Med Rep; 2018 Jan; 17(1):562-570. PubMed ID: 29115608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-29a inhibits invasion and metastasis of cervical cancer via modulating methylation of tumor suppressor SOCS1.
    Gong Y; Wan JH; Zou W; Lian GY; Qin JL; Wang QM
    Future Oncol; 2019 May; 15(15):1729-1744. PubMed ID: 31038361
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.